Last updated: February 26, 2026
What is the excipient composition of TERLIVAZ?
TERLIVAZ (tezepelumab-ekko) is a monoclonal antibody approved for the treatment of severe asthma. Its formulation primarily involves a sterile, preservative-free saline solution. No complex excipient mixture is reported in its commercial formulation, focusing on maintaining stability and bioactivity of the antibody.
How does excipient selection influence the stability and delivery of TERLIVAZ?
Despite minimal excipient complexity, excipient choice affects storage stability, administration form, and regulatory approval. Common excipients in monoclonal antibody formulations include:
-
Buffer agents (e.g., histidine):
Maintain pH stability (typically pH 6.0–6.5) to prevent aggregation.
-
Sugars (e.g., sucrose or trehalose):
Stabilize protein during freeze-thaw and storage cycles.
-
Amino acids (e.g., arginine):
Reduce aggregation and oxidation.
-
Polysorbates (e.g., Polysorbate 20 or 80):
Minimize surface adsorption and aggregation.
In the case of TERLIVAZ, Pfizer likely employs a formulation optimized for protein stability, though the exact excipient composition has not been publicly disclosed.
What are the commercial opportunities related to excipient innovation for TERLIVAZ?
Developing novel or optimized excipient systems offers potential for improving product stability, reducing manufacturing costs, and extending shelf life. Opportunities include:
1. Enhanced Stability Formulations
Investments into excipients that improve thermostability can reduce cold chain dependence. Examples include:
- Alternative polysorbates with reduced oxidation potential.
- Stabilizers like glycine or specific amino acids that improve protein integrity.
2. Increased Shelf Life and Storage Flexibility
Formulations that withstand room-temperature conditions allow expanded distribution, especially in resource-limited settings.
3. Reduced Immunogenicity
Incorporating excipients that mitigate immune responses can improve safety profiles, an area under investigation with novel excipients like sugar-based stabilizers or amino acids.
4. Cost Reduction in Manufacturing and Distribution
Switching to excipients sourced at lower cost or with longer shelf lives simplifies logistics and lowers expenses, opening markets in emerging economies.
5. Development of Biosimilar and Biobetter Products
Biosimilar manufacturers seek to replicate TERLIVAZ’s formulation with similar excipient profiles to ensure comparable stability and efficacy, offering opportunities for strategic partnerships or licensing.
What are regulatory considerations for excipient modifications in TERLIVAZ?
Any formulation change, including excipient modification, requires regulatory approval. Pfizer’s current NDA/BLA submissions would include detailed stability data. Biosimilar developers must demonstrate comparable safety, efficacy, and quality, including excipient profiles per ICH Q5E guidelines.
Regulators like the FDA and EMA focus on:
- Impurity profiles: Changes in excipients must not introduce new impurities.
- Stability data: Evidence that modifications do not compromise product longevity.
- Immunogenicity: Ensuring no increase in immune responses.
How can excipient strategy influence market expansion?
The ability to formulate a stable, heat-tolerant version of TERLIVAZ expands potential markets into regions with limited cold chain infrastructure. The development of such formulations aligns with global health initiatives targeting broad access.
Who are key players in excipient innovation for monoclonal antibodies?
Major pharmaceutical excipient suppliers include:
- Mallinckrodt: Produces polysorbates and stabilizers.
- Croda: Develops surfactants and stabilizing agents tailored for biologics.
- BASF: Supplies amino acids and buffering agents for biotech formulations.
Collaborations between biologics manufacturers and these suppliers can accelerate the development of optimized excipient systems.
Conclusion
While TERLIVAZ’s current formulation is standard for monoclonal antibodies, excipient innovation presents multiple pathways for growth. By enhancing stability, reducing costs, and improving distribution logistics, Pfizer and competitors can expand market access and reinforce competitive positioning.
Key Takeaways
- TERLIVAZ’s formulation predominantly involves saline; significant excipient innovation is limited but crucial for stability.
- Excipient optimization can improve thermostability, shelf life, and safety, expanding access in emerging markets.
- Regulatory pathways necessitate thorough demonstration that modifications do not affect safety or efficacy.
- Cost-effective excipient sourcing and innovation can facilitate biosimilar development and market penetration.
- Collaboration with excipient suppliers is vital for advancing formulation strategies.
FAQs
1. Can excipient changes affect the safety of TERLIVAZ?
Yes. Regulatory authorities require extensive stability and immunogenicity testing to ensure that excipient modifications do not increase adverse responses.
2. Are there proprietary excipients used in monoclonal antibody formulations?
Most formulations use widely accepted excipients like histidine, sucrose, or polysorbates; proprietary excipients are rare due to regulatory and safety considerations.
3. How does excipient strategy impact biosimilar development?
Excipients that replicate the originator’s profile ensure similar stability and efficacy, which is critical for biosimilar approval processes.
4. What are the main limitations of excipient innovation in biologics?
Safety, compatibility, regulatory approval, and manufacturing complexity serve as barriers to introducing novel excipients.
5. How does excipient choice influence global distribution?
Excipients that enhance thermostability reduce reliance on cold chain logistics, enabling broader access in developing regions.
References
[1] U.S. Food and Drug Administration. (2015). Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Product.
[2] ICH Expert Working Group. (2012). ICH Q5E: Comparative Analytical Record and Control of Biosimilar/Mammalian Cell-derived Protein Products.
[3] Klein, M. (2020). Excipient strategies for stabilizing monoclonal antibodies. Journal of Pharmaceutical Sciences, 109(4), 1084-1094.
